Sign In
Buy AXNX
$70.98
+0 (+0%)
At Close: Feb 13, 2025
Axonics, Inc. (AXNX) Q1 2023 Earnings Call Transcript
09:36pm, Monday, 01'st May 2023
Axonics, Inc. (NASDAQ:AXNX ) Q1 2023 Earnings Conference Call May 1, 2023 4:30 PM ET Company Participants Neil Bhalodkar - VP of IR Raymond Cohen - CEO Dan Dearen - President and CFO Conference Call P
Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates
07:01pm, Monday, 01'st May 2023
Axonics Modulation Technologies (AXNX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago.
Axonics to Report First Quarter 2023 Financial Results on May 1
06:00am, Monday, 10'th Apr 2023
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct
Axonics, Inc. (AXNX) Q4 2022 Earnings Call Transcript
10:59pm, Wednesday, 01'st Mar 2023
Axonics, Inc. (NASDAQ:AXNX ) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Neil Bhalodkar - VP of IR Raymond Cohen - CEO Dan Dearen - President and CFO Conference Call
Axonics Modulation Technologies (AXNX) Surpasses Q4 Earnings and Revenue Estimates
06:48pm, Wednesday, 01'st Mar 2023
Axonics (AXNX) delivered earnings and revenue surprises of 104.35% and 0.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Axonics (AXNX) Might Surprise This Earnings Season
09:48am, Tuesday, 28'th Feb 2023
Axonics (AXNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Axonics to Report Fourth Quarter 2022 Financial Results on March 1
04:30pm, Wednesday, 08'th Feb 2023
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct
6 Favorite Biotech Bets For 2023
10:48am, Monday, 09'th Jan 2023
Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception; here's
3 Hot Stocks Going Into the Holiday Weekend
02:18pm, Friday, 23'rd Dec 2022
All three of these top-ranked stocks have recently gone on nice runs, giving shareholders some holiday cheer. Can the strength spill over into the new year?
Axonics to Present at the 41st Annual J.P. Morgan Healthcare Conference
06:00am, Wednesday, 21'st Dec 2022
IRVINE, Calif.--( BUSINESS WIRE )--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfun
Is Axonics (AXNX) Outperforming Other Medical Stocks This Year?
11:17am, Monday, 19'th Dec 2022
Here is how Axonics Modulation Technologies (AXNX) and GlycoMimetics (GLYC) have performed compared to their sector so far this year.
2 Fast-Growing Healthcare Stocks to Buy and Hold
07:10am, Friday, 02'nd Dec 2022
The innovative companies have made great gains in a short period of time.
Axonics: Reaffirm Buy Following Q3 Strengths, Guidance Upgrade
03:48am, Thursday, 24'th Nov 2022
Following its Q3 FY23 financial results, AXNX management raised FY22 revenue guidance to $262mm, calling for 45% growth. Sacral neuromodulation revenue booked a record $59.6mm for the 3rd FY22 quarter
Are Medical Stocks Lagging Axonics (AXNX) This Year?
11:18am, Wednesday, 16'th Nov 2022
Here is how Axonics Modulation Technologies (AXNX) and GlycoMimetics (GLYC) have performed compared to their sector so far this year.
Axonics, Inc. (AXNX) Q3 2022 Earnings Call Transcript
12:09am, Tuesday, 01'st Nov 2022
Axonics, Inc. (NASDAQ:AXNX ) Q3 2022 Earnings Conference Call October 31, 2022 4:30 PM ET Company Participants Neil Bhalodkar - Vice President of Investor Relations Raymond Cohen - Chief Executive Off
